Scripps Health/the Medicines Company announce late breaking BRIDGE trial results presented at TCT
The BRIDGE trial results demonstrate that cangrelor maintains target levels of platelet inhibition, supporting its use as a management strategy for patients requiring prolonged platelet P2Y12 inhibition after thienopyridine discontinuation. The study showed 99% of cangrelor-treated patients maintained target levels, compared to 19% of ...